Immunitybio (IBRX) Aandeel Koers

Immunitybio Inc is primarily active in the fields of biotechnology and immunotherapy. As a leading biotech company, Immunitybio Inc focuses on developing breakthrough treatments and therapies that harness the power of the immune system to combat diseases. With a strong emphasis on research and innovation, Immunitybio Inc aims to revolutionize healthcare by providing effective solutions for various medical conditions. Through its cutting-edge advancements in biotechnology and immunotherapy, Immunitybio Inc is dedicated to improving patient outcomes and making a significant impact in the industry.

The main competitors of Immunitybio Inc in the market are companies like Moderna Inc, BioNTech SE, Novavax Inc, and AstraZeneca PLC.

Immunitybio Inc is a leading biotechnology company known for its innovative immunotherapy treatments. Established in [year], Immunitybio has a rich history of developing groundbreaking therapies to combat various diseases. With a strong focus on cancer research, the company has made significant strides in revolutionizing the field of oncology. Immunitybio's cutting-edge technologies and advanced scientific approaches have positioned it as a key player in the biotech industry. Its dedication to improving patient outcomes and advancing medical knowledge has garnered widespread recognition and put Immunitybio at the forefront of the fight against cancer and other illnesses.

Immunitybio Inc has achieved several significant milestones. The company has made breakthrough advancements in the field of immunotherapy, with a focus on developing innovative treatments for cancer and infectious diseases. Immunitybio Inc has successfully conducted clinical trials to demonstrate the efficacy and safety of its novel therapies. Additionally, the company has secured strategic partnerships with leading institutions and organizations, further validating its scientific expertise. With its strong commitment to research and development, Immunitybio Inc continues to make remarkable progress in improving patient outcomes and revolutionizing the field of immunotherapy.

Immunitybio Inc is primarily present in the United States.

Immunitybio Inc represents values of innovation, resilience, and commitment to advancing healthcare. Committed to developing and delivering cutting-edge immunotherapies and vaccines, Immunitybio Inc aims to revolutionize the treatment of various diseases. With a strong corporate philosophy centered around patient-centricity and scientific excellence, the company strives to bring about positive changes in global healthcare. Immunitybio Inc seeks to harness the power of the immune system to combat diseases and improve patient outcomes. By combining expertise, technology, and a passion for improving lives, Immunitybio Inc is dedicated to making a significant impact in the field of immunotherapy and beyond.

Analisten hanteren momenteel een gemiddeld koersdoel van 13,00 USD voor het aandeel Immunitybio (mediaan: 12,00 USD), oftewel +56,8 % ten opzichte van de laatste koers. De consensus is gebaseerd op 10 analistenratings.

Immunitybio Koersdoelstellingen analisten 2026

10 analisten beoordelen het aandeel Immunitybio momenteel: 9 adviseren kopen, 1 houden en 0 verkopen. Voor 2026 verwachten analisten dat Immunitybio een omzet van 226,56 Miljoen USD en winst per aandeel van -0,68 USD behaalt.

Immunitybio Koersdoelstellingen analisten 2026

Omgezet tegen de huidige wisselkoers noteert het aandeel Immunitybio op 7,89 EUR (8,81 USD).

Het aandeel Immunitybio (IBRX) is genoteerd aan 4 beurzen, waaronder: NASDAQ (IBRX), Frankfurt (26CA.F), München (26CA.MU), Düsseldorf (26CA.DU).

Immunitybio Inc is a US biotechnology company focused on developing immunotherapies. The company operates in three main areas: oncology, infectious diseases, and autoimmune diseases. Its goal is to produce innovative drugs that strengthen the immune system and fight diseases. Immunitybio focuses on developing cancer drugs that activate the immune system and target cancer cells. The company offers a range of immunotherapies based on different compounds and technologies. Its flagship product in oncology is the drug N-803, which aims to activate T-cells in the body and fight cancer. Immunitybio is currently conducting clinical trials with N-803 to evaluate its efficacy. In the field of infectious diseases, Immunitybio is developing vaccines and immunotherapies against various diseases such as influenza, HIV, and COVID-19. The company recently initiated a COVID-19 vaccine study testing a vaccine based on an adenoviral vector containing the spike protein of the virus. It is also working on developing vaccines against other infectious diseases such as dengue fever and malaria. In the field of autoimmune diseases, Immunitybio focuses on developing immunotherapies that can better regulate autoimmunity. The company is developing drugs based on various compounds, including T-cell receptor mimetics and antibodies against specific immune cells. Immunitybio has also developed a T-cell therapy that can be used for multiple sclerosis. In addition, Immunitybio offers services in genetic engineering and protein production. The company has an extensive platform technology used for the production of proteins, antibodies, and vaccines. It also offers customized proteins and antibodies for various applications. Immunitybio has established a strong partnership with the University of California, Los Angeles (UCLA) to support its research and development activities. The company has also formed partnerships with other companies and organizations in the healthcare sector to further enhance its products and services. Immunitybio's business model is based on the development and commercialization of immunotherapies and vaccines for different diseases. The company has a strong research and development pipeline and collaborates closely with other companies and organizations to expand its product and service offerings. With a robust platform technology and dedicated leadership, Immunitybio has the potential to revolutionize the healthcare industry and improve disease treatments.

De verwachte omzet van Immunitybio bedraagt 226,56 Miljoen USD. Deze cijfers zijn gebaseerd op huidige financiële gegevens en weerspiegelen de bedrijfsresultaten van het bedrijf.

De verwachte winst van Immunitybio bedraagt -669,42 Miljoen USD. De nettowinst weerspiegelt de rentabiliteit van het bedrijf na aftrek van alle kosten.

De koers-winstverhouding (P/E) van Immunitybio bedraagt momenteel -13,02. De P/E-ratio vergelijkt de huidige aandeelkoers met de winst per aandeel en helpt beleggers de waardering van het Immunitybio-aandeel in te schatten.

De koers-omzetverhouding (P/S) van Immunitybio bedraagt momenteel 38,48. De P/S-ratio vergelijkt de marktkapitalisatie met de jaarlijkse opbrengsten en dient als waarderingsmaatstaf voor het Immunitybio-aandeel.

De Eulerpool Kwaliteitsscore voor Immunitybio is 6/10.

De ISIN van Immunitybio is US45256X1037. De ISIN (International Securities Identification Number) is een wereldwijd unieke identificatie voor wertpapieren.

De WKN van Immunitybio is A2QQ2E. De WKN (Wertpapierkennnummer) is een zescijferig Duits identificatienummer voor wertpapieren.

Het tickersymbool van Immunitybio is IBRX. Onder dit beurstickersymbool wordt het Immunitybio-aandeel op de beurs verhandeld.